Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094119 | 0.86 | DRD4 (0.31) | OPRM1 | |
| SCHEMBL24865146 | 0.79 | GAA (0.31) | GAAMAPK1 | |
| SCHEMBL11911969 | 0.79 | — | — | |
| SCHEMBL25451973 | 0.77 | KDM4E (0.35) | — | |
| SCHEMBL25450606 | 0.76 | OPRM1 (0.37) | OPRM1 | |
| SCHEMBL18717730 | 0.75 | — | — | |
| SCHEMBL12389984 | 0.74 | — | — | |
| SCHEMBL12553802 | 0.74 | — | — | |
| SCHEMBL23344999 | 0.73 | CYP1A2 (0.39) | MAPK1 | |
| SCHEMBL23345005 | 0.73 | CYP2D6 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | GAA 4392/4885MAPK1 11/4885OPRM1 4372/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | GAA 4392/4885MAPK1 195/4885OPRM1 4659/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | GAA 1568/4885MAPK1 400/4885OPRM1 1247/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | GAA 990/4885MAPK1 1815/4885OPRM1 572/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | GAA 889/4885MAPK1 4173/4885OPRM1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.